Enlivex Therapeutics Ltd (NASDAQ: ENLV) closed the day trading at $1.83 down -54.02% from the previous closing price of $3.98. In other words, the price has decreased by -$2.1500 from its previous closing price. On the day, 2793262 shares were traded.
Ratios:
For a better understanding of ENLV, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.57 and its Current Ratio is at 5.57. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on March 02, 2021, Reiterated its Buy rating but revised its target price to $33 from $22 previously.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ENLV now has a Market Capitalization of 74.02M and an Enterprise Value of 48.04M.
Stock Price History:
Over the past 52 weeks, ENLV has reached a high of $4.59, while it has fallen to a 52-week low of $1.20. The 50-Day Moving Average of the stock is 3.4478, while the 200-Day Moving Average is calculated to be 2.4791.
Shares Statistics:
Over the past 3-months, ENLV traded about 88.04K shares per day on average, while over the past 10 days, ENLV traded about 410.23k shares per day. A total of 18.60M shares are outstanding, with a floating share count of 14.97M. Insiders hold about 19.44% of the company’s shares, while institutions hold 1.64% stake in the company. Shares short for ENLV as of Mar 15, 2024 were 261.46k with a Short Ratio of 2.68, compared to 149.89k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.41% and a Short% of Float of 1.50%.
Earnings Estimates
Current recommendations for the stock of the company come from 1 analysts. On average, analysts expect EPS of -$0.21 for the current quarter, with a high estimate of -$0.21 and a low estimate of -$0.21, while EPS last year was -$0.39. The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.21 and low estimates of -$0.21.
Analysts are recommending an EPS of between -$0.86 and -$0.86 for the fiscal current year, implying an average EPS of -$0.86. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.
